{
    "Trade/Device Name(s)": [
        "Lingo Glucose System"
    ],
    "Submitter Information": "Abbott Diabetes Care, Inc.",
    "510(k) Number": "K233655",
    "Predicate Device Reference 510(k) Number(s)": [
        "K222447"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "SAF"
    ],
    "Summary Letter Date": "November 13, 2023",
    "Summary Letter Received Date": "November 14, 2023",
    "Submission Date": "May 29, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Lingo Glucose Biosensor",
        "Lingo App (iOS)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric electrochemical sensor",
        "Glucose oxidase chemical reaction",
        "Bluetooth Low Energy (BLE)",
        "Near-Field Communication (NFC)"
    ],
    "Methodologies": [
        "Continuous glucose monitoring"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "App",
        "Applicator",
        "Pack"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Lingo Glucose System, an OTC integrated continuous glucose monitor for real-time glucose measurement using a wearable biosensor and mobile app",
    "Indications for Use Summary": "Intended for OTC continuous measurement, recording, analysis, and display of glucose values in adults (18+) not on insulin to aid understanding of glucose dynamics and effects of lifestyle/behavior modification; not for medical action without healthcare consultation",
    "fda_folder": "Clinical Chemistry"
}